All In Biotech

Drug Trial Radar · NCT07908537

A Clinical Trial of Gocatamig (MK-6070) With Durvalumab in Participants With Small Cell Lung Cancer (MK-6070-004)

A Phase 3 Randomized Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) in Combination With Durvalumab Compared to Durvalumab Alone as Consolidation Therapy in Participants With Limited-Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 564 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

564

Planned (sponsor's estimate)

Start

Dec 7, 2026

Primary completion

Dec 8, 2031

Study completion Mar 10, 2036

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
Daiichi Sankyo
First posted
Nov 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat limited-stage small cell lung cancer (LS-SCLC). LS-SCLC is a type of lung cancer that has not spread from the lung to other parts of the body. Researchers want to learn if gocatamig given with durvalumab can treat LS-SCLC. The main goal of this trial is to learn if participants who receive gocatamig with durvalumab live longer without the cancer getting worse than those who receive durvalumab alone.

Conditions

  • Small Cell Lung Cancer

Interventions

  • GocatamigBiological

    Intravenous (IV) infusion

  • DurvalumabBiological

    IV infusion

  • Rescue MedicationsDrug

    Participants will receive rescue medications at the investigator's discretion. Recommended rescue medications include tocilizumab and/or siltuximab for treatment of cytokine release syndrome (CRS) and dexamethasone, acetaminophen, and diphenhydramine for CRS/infusion-related reaction prophylaxis.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: Up to approximately 59 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.